EWTX
Edgewise Therapeutics, Inc.
Biotechnology · Healthcare · United States
38.90
close · 2026-10-30
value
97
cheaper than peers97
quality
85
stronger fundamentals85
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 3 years ago | -0.8% | 98 |
| earnings yield, 1 year ago | -1.1% | 97 |
| earnings yield, 2 years ago | -4.0% | 92 |
| cash flow yield, 3 years ago | -1.4% | 90 |
| earnings yield, latest year | -4.2% | 89 |
| cash flow yield, latest year | -3.4% | 87 |
| cash flow yield, 2 years ago | -2.3% | 87 |
| cash flow yield, 1 year ago | -2.6% | 85 |
| price to book | 9.36× | 14 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -38.1% | 77 |
| debt to equity | 0.8% | 77 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $4B |
| free cash flow | -$90.5M |
| employees | 154 |
| first trade | 2021-03-26 |
| next earnings | 2026-08-06 |
| fundamentals updated | 2026-08-06 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.63 | -0.42 | -1.57 | -0.31 |
| free cash flow | -$144.1M | -$110.3M | -$97.7M | -$58.2M |
| net income | -$167.8M | -$133.8M | -$100.2M | -$67.6M |
| revenue | $0 | $0 | $0 | $0 |